Moscow, Russia, July 25, 2017 – InSysBio LLC (www.insysbio.ru), one of the pioneers in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development, announced today a renewal of multi-year Master Service Agreement with ASTEX Pharmaceuticals, Inc.
Within the framework of this cooperation, InSysBio provides priority support for ASTEX research. This gives an opportunity to access the best practices of InSysBio in the field of QSP modeling, as well as significantly reduce the time of initiation and execution of projects.
The renewal of the ASTEX agreement once again shows that QSP is a necessary technology to support discovery and development of new drugs in oncology and immuno-oncology therapeutic areas. Such an approach improves all stages of the development: it helps to make strategic GO/ NO GO decisions for research, prioritize targets and compounds, interpret results from animal studies and select optimal design(s) for clinical trials.
"We are very pleased ASTEX has chosen to renew our multi-year Master Service Agreement. It underscores that our partners are satisfied with our services and would like to extend this fruitful and reliable collaboration," said Founder and CEO Oleg Demin, PhD.
| ← | October 2025 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
1.
02 Oct 2025 13:23
InSysBio to announce participation in BioTechX Europe 2025 with focus on AI and QSP
InSysBio announces their participation in BioTechX Europe 2025. Oleg Demin, Chief Scientific Advisor and co-founder of InSysBio, and Igor Goryanin, Professor at University of Edinburgh, will host a roundtable discussion entitled, "Integrating Artificial Intelligence with Quantitative Systems Pharmacology (QSP): Opportunities and Challenges"
|
3
|
4
|
5
| ||
|
6
|
7
|
8
|
9
|
10
|
11
|
12
|
|
13
|
14
|
15
|
16
1.
16 Oct 2025 12:13
InSysBio to introduce a new data annotation service available in CYTOCON DB and fIVE DB
InSysBio launches a new data annotation service designed to support researchers and analysts who require specific, literature-based biological data to be added to InSysBio’s CYTOCON or fIVE databases for use in QSP modeling, analysis, or decision-making. The new service allows clients to submit targeted data requests related to diseases, tissues, cell types, and cytokines
|
17
|
18
|
19
|
|
20
|
21
|
22
|
23
|
24
|
25
|
26
|
|
27
|
28
|
29
1.
29 Oct 2025 15:08
The project aims at mechanistic PK/RO modeling to predict optimal dose and regimen of BGB-B2033, GPC3 x 4-1BB bispecific antibody
InSysBio, one of the world's pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces its collaboration with BeOne Medicines, a global oncology company.
|
30
|
31
| ||
Thank you for your message! We will get back to you shortly.
